- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- II Somatic Interventions
- 18 Stimulants
- 19 <span xml:lang="ell">α</span><sub>2</sub>-Adrenergic Agonists: Clonidine and Guanfacine
- 20 Antidepressants I: Selective Serotonin Reuptake Inhibitors
- 21 Antidepressants II: Other Agents
- 22 Mood Stabilizers: Lithium, Anticonvulsants, and Others
- 23 Antipsychotic Agents: Traditional and Atypical
- 24 Anxiolytics and Sedative/Hypnotics: Benzodiazepines, Buspirone, and Others
- III Assessment and Treatment
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index
(p. 297) Mood Stabilizers: Lithium, Anticonvulsants, and Others
- Chapter:
- (p. 297) Mood Stabilizers: Lithium, Anticonvulsants, and Others
- Author(s):
Robert A. Kowatch
, Jeffrey R. Strawn
, and Arman Danielyan
- DOI:
- 10.1093/med/9780195398212.003.0022
Chapter 22 reviews the mechanism of action of mood stabilizers, which can be divided into the traditional agents — lithium, valproate, and carbamazepine — and the newer or “novel” agents, which include lamotrigine, oxcarbazepine, topiramate, gabapentin, and pregabalin, and the pharmacokinetic and clinical factors important to be aware of when these agents are used to treat children and adolescents.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- II Somatic Interventions
- 18 Stimulants
- 19 <span xml:lang="ell">α</span><sub>2</sub>-Adrenergic Agonists: Clonidine and Guanfacine
- 20 Antidepressants I: Selective Serotonin Reuptake Inhibitors
- 21 Antidepressants II: Other Agents
- 22 Mood Stabilizers: Lithium, Anticonvulsants, and Others
- 23 Antipsychotic Agents: Traditional and Atypical
- 24 Anxiolytics and Sedative/Hypnotics: Benzodiazepines, Buspirone, and Others
- III Assessment and Treatment
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index
